Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2005 Mar;2(3):e77; author reply e95.
doi: 10.1371/journal.pmed.0020077. Epub 2005 Mar 29.

Tumor cell recognition efficiency by T cells

Comment

Tumor cell recognition efficiency by T cells

Daniel E Speiser et al. PLoS Med. 2005 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Comment on

References

    1. Stuge TB, Holmes SP, Saharan S, Tuettenberg A, Roederer M, et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 2004;1:e28. - PMC - PubMed
    1. Men Y, Miconnet I, Valmori D, Rimoldi D, Cerottini JC, et al. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. J Immunol. 1999;162:3566–3573. - PubMed
    1. Valmori D, Fonteneau JF, Marañón Lizana C, Gervois N, Liénard D, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogs. J Immunol. 1998;160:1750–1758. - PubMed
    1. Ayyoub M, Zippelius A, Pittet MJ, Rimoldi D, Valmori D, et al. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/MART-1. Clin Cancer Res. 2003;9:669–677. - PubMed
    1. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: A state of local functional tolerance. Cancer Res. 2004;64:2865–2873. - PubMed